Why Is Prior Authorization for Dupixent So Crucial for Your Patients? (2026 Guide)

Written By

Dan Nandan

25+ Years Healthcare Outsourcing. CEO, Staffingly

▼

Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.

2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.

Featured in Computerworld →

Clinically Reviewed By

Bincy Kuriakose, MSN, RN

Clinical Content Reviewer. IL RN License #041.577729

▼

State of Illinois. Registered Professional Nurse

Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.

Step-by-Step Prior Authorization Process for Dupixent

Step 1 – Confirm Dupixent Is the Right Treatment

• Evaluate patient's condition against FDA-approved indications
• Ensure first-line therapies have been documented as tried and failed
• For AD: topical corticosteroids, calcineurin inhibitors (most plans require 1-2 failures)
• For asthma: confirm eosinophilic phenotype (eosinophils 150+ cells/mcL) or OCS dependence, confirm max ICS/LABA
• For EoE: document PPI failure (8+ weeks), endoscopy with biopsy

Step 2 – Gather Documentation

• Medical records, lab results (eosinophil counts, IgE, BSA measurements)
• Treatment history with specific: drug name, dose, duration, clinical response, reason for discontinuation
• Use the DUPIXENT MyWay PA Checklist (from dupixenthcp.com) to ensure nothing is missing
• Include photos for dermatologic indications

The documentation step is where most Dupixent PAs fail on first submission. Payers want granular detail, not summaries. “Failed topical steroids” is not enough. The PA submission should read: “Patient used triamcinolone acetonide 0.1% cream, applied twice daily to affected areas for 8 weeks (March 1 through April 25, 2026), with documented BSA remaining at 18% and EASI score of 24.3 at follow-up.” That level of specificity matches what the payer’s clinical reviewer needs to approve the request without requesting additional information. Every round of additional information requests adds 7-14 days to the approval timeline.

Step 3 – Submit the PA Request

• Obtain the PA form via DUPIXENT MyWay, CoverMyMeds, or the patient's payer directly
• Submit electronically when possible (faster turnaround, fewer lost-document issues)
• Standard processing: 3-5 business days. Expedited (urgent): 24-48 hours

Step 4 – If Denied, File an Appeal

• Review the denial letter carefully to identify the specific reason
• Request a peer-to-peer review with the payer's medical director
• Submit a letter of medical necessity citing clinical guidelines and specific lab values
• Request external review if internal appeal is denied (state-specific rights apply)
• Pennsylvania external review overturns approximately 50% of denials
• California IMR process overturns 55-68% of medical necessity denials

Step 5 – Track and Follow Up

• Create a tracking system for all PA submissions, responses, and deadlines
• Set calendar reminders for reauthorization (most plans require every 6-12 months)
• DUPIXENT MyWay case managers (1-844-387-4936) can assist with status tracking

Dupixent Coverage Criteria by Indication

Coverage criteria are not uniform. Each FDA-approved indication carries its own documentation threshold, and submitting against the wrong criteria is a frequent cause of denial. For atopic dermatitis, payers look for BSA percentage and EASI or SCORAD scoring with documented failure of topical corticosteroids and calcineurin inhibitors. For asthma, plans require an eosinophil count of 150 cells/mcL or higher and confirmed maximum ICS/LABA use. For eosinophilic esophagitis, payers want documented PPI failure of 8 or more weeks plus endoscopy with biopsy. CRSwNP, prurigo nodularis, COPD, and CSU each carry indication-specific criteria, so confirm the individual payer policy before every submission.

ICD and CPT Codes for Dupixent Prior Authorization

ICD-10 Codes

CPT / HCPCS Codes

Note: Correct coding prevents denials due to code mismatch. Always confirm the payer’s required HCPCS code, as some plans use drug-specific J-codes when available. Some Medicare Part D plans and commercial specialty pharmacies require NDC-level coding on claims rather than HCPCS codes, particularly for specialty pharmacy dispensing. Confirm with each payer whether the claim should be coded at the HCPCS level (for medical benefit) or NDC level (for pharmacy benefit), because submitting to the wrong benefit channel is a denial that cannot be corrected through appeal, only through resubmission to the correct benefit.

A common coding error on Dupixent PAs involves submitting a non-specific ICD-10 code when a more specific option exists. For atopic dermatitis, L20.89 (other atopic dermatitis) with documented BSA percentage is stronger than L20.9 (unspecified). For asthma, specify the severity level (J45.30 for mild persistent, J45.40 for moderate persistent, J45.50 for severe persistent) rather than defaulting to J45.909. Payers reviewing Dupixent PAs look for specificity because the drug is approved only for moderate-to-severe conditions, and a non-specific code does not confirm the severity threshold the payer requires for coverage.

Dupixent PA Rules by State: Georgia, Pennsylvania, Illinois

Georgia

• Georgia Medicaid (CareSource) covers Dupixent for AD when BSA is 10%+ or highly visible/functional areas are affected with significant quality-of-life impact
• Requires documented failure of topical therapies
• No state-level step therapy ban for commercial plans
• (Source: CareSource GA Medicaid Policy, July 2024)

Pennsylvania

• Most commercial plans (Humana, Highmark, etc.) place Dupixent on Tier 4 specialty
• Standard PA processing: 14-30 days. Expedited: 72-hour turnaround
• Act 90 of 2018 provides step therapy override protections for commercial insurance
• External review program overturns approximately 50% of denials
• PA Insurance Dept. consumer help: 1-877-881-6388
• Highmark offers a specific Dupixent PA form (Source: Highmark provider portal)

Illinois

• Illinois HFS Medicaid Preferred Drug List includes Dupixent (most recent update: January 2026)
• Some managed Medicaid plans (e.g., BCBS IL BCCHP) list Dupixent as non-preferred, requiring PA
• SB 1549 (effective 2020) requires step therapy override provisions for commercial plans
• Molina, Meridian, and other MCOs have their own PA criteria that may differ from the state PDL

Common Reasons Dupixent PA Gets Denied (and How to Fix Each One)

Six Common Dupixent PA Mistakes That Delay Patient Access

Practices managing Dupixent PAs run into the same six errors that account for most preventable denials. Fixing these raises first-pass approval rates significantly.

1. Submitting without specifying the indication-specific criteria. A PA form that lists “atopic dermatitis” without BSA percentage, EASI score, or clinical photos is rejected for insufficient documentation. Every indication has specific clinical measures. Use them.

2. Documenting “tried topicals” instead of specific trials. Each prior therapy needs drug name, dose, duration (minimum 4-6 weeks typically), and documented clinical outcome. Vague language like “failed conservative therapy” is the single most common cause of first-pass denials.

3. Missing the eosinophil count for asthma PAs. Plans covering Dupixent for asthma want an eosinophil count of 150 cells per microliter or higher documented within the past 6 months. A current CBC with differential is standard. Without it, the PA defaults to denial. Some payers also require documentation of FEV1 values showing persistent airflow limitation despite maximum inhaled corticosteroid and long-acting beta-agonist therapy. Including both the eosinophil count and FEV1 data in the initial submission eliminates the most common request-for-additional-information cycle on asthma Dupixent PAs.

4. Ignoring state step therapy override laws. Pennsylvania Act 90 and Illinois SB 1549 give providers the right to request step therapy exceptions when the required drugs are inappropriate for a specific patient. Practices that submit straight PAs in these states without invoking the override law lose a faster appeal path.

5. Not using the DUPIXENT MyWay case manager. Regeneron assigns case managers who can track PA status, provide payer-specific documentation guidance, and expedite escalations. Practices that submit and wait in silence miss the active case management support available at 1-844-387-4936.

6. Missing the reauthorization window. Dupixent reauthorizations typically require documented clinical benefit every 6-12 months. Practices that wait until the pharmacy rejects the refill force the patient into a therapy gap. Flag renewal 60-90 days before expiration.

How Staffingly Helps Providers With Dupixent Prior Authorization

Staffingly provides trained PA specialists who handle the entire Dupixent PA lifecycle: benefits investigation, formulary verification, initial PA submission, clinical documentation assembly, payer follow-up, denial appeals including peer-to-peer scheduling, and reauthorization management. The team is trained specifically on payer-specific Dupixent criteria and works alongside the DUPIXENT MyWay PA checklist to ensure every submission meets the individual payer’s coverage policy requirements.

For dermatology and allergy practices managing 20 to 50 active Dupixent patients, PA work alone can consume 20 to 40 staff hours per week between initial submissions, follow-up calls, and renewal management. Staffingly handles this entire volume at $399/week (volume discounts to $299/week) with 70% cost savings compared to in-house equivalents. The team integrates across 50+ EHR platforms with 48-72 hour go-live, maintains a 99.2% clean claim rate across 800+ providers, and holds SOC 2 Type II, HITRUST, ISO 27001, and HIPAA certifications.

The 15-Day Risk-Free Pilot covers real Dupixent PA submissions on your actual patient panel so you can measure approval rates, turnaround times, and staff time savings before any long-term commitment. Book A Strategy Call to discuss your practice’s Dupixent PA volume and payer mix.

Prior authorization requirements continue to increase across all payer types. The AMA’s 2024 Prior Authorization Physician Survey found that physicians complete an average of 43 PA requests per week, with each request consuming significant staff time. For practices handling specialty medications, imaging studies, or surgical procedures, the PA workload can consume 12 or more staff hours per week. That is time pulled directly from patient care activities and revenue-generating tasks.

The financial impact goes beyond staff time. Delayed authorizations mean delayed treatment, which affects patient satisfaction scores and can trigger downstream complications that cost more to treat. Practices report that PA-related delays contribute to appointment cancellations, no-shows, and patient attrition to competitors who can get approvals faster. When a patient waits two weeks for an authorization that should have taken three days, the practice relationship suffers regardless of whether the delay was the payer’s fault or the staff’s.

The denial rate for prior authorizations adds another layer of cost. When a PA request is denied, staff must research the reason, gather additional documentation, schedule peer-to-peer reviews with payer medical directors, and file formal appeals. Each denied PA represents 3-5 additional hours of staff work beyond the initial submission. Multiply that across dozens of denials per month and the cost becomes unsustainable for many practices.

Outsourcing PA to a dedicated team with payer-specific expertise addresses both the time and quality problems. Staffingly’s PA specialists handle the full authorization lifecycle from initial submission through peer-to-peer reviews and formal appeals. Working across 50+ EHR platforms and serving 800+ providers, Staffingly goes live within 48-72 hours at $399/week (volume discounts to $299/week) with a 99.2% clean claim rate. The 15-Day Risk-Free Pilot lets practices test the service with zero upfront cost and no long-term contract required.

Frequently Asked Questions